The rs3761548 FOXP3 variant is associated with multiple sclerosis and transforming growth factor β1 levels in female patients
The aim of this study was to evaluate the association between rs3761548 FOXP3 (-3279 C > A) variant and multiple sclerosis (MS), disability, disability progression, as well as transforming growth factor (TGF)-β1 and interleukin (IL)-10 plasma levels in MS patients.
Methods and subjects
The study included 170 MS patients and 182 controls. Disability was evaluated using Expanded Disability Status Scale (EDSS) and categorized as mild (EDSS ≤ 3) and moderate/high (EDSS > 3). Disability progression was evaluated using Multiple Sclerosis Severity Score (MSSS). The rs3761548 variant was determined with polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP). Plasma levels of TGF-β1 and IL-10 were determined using immunofluorimetric assay.
CA and AA genotypes were associated with MS [odds ratio (OR) 2.03, 95% confidence interval (CI) 1.66–3.53, p = 0.012; OR 8.19, 95% CI 3.04–22.07, p < 0.001, respectively). With the dominant model, the CA + AA genotypes were associated with MS (OR 2.57, 95% CI 1.50–4.37, p < 0.001). In the recessive model, the AA genotype was also associated with MS (OR 5.38, 95% CI 2.12–13.64, p < 0.001). After adjustment by age, ethnicity, BMI and smoking, all these results remained significant, as well as female patients carrying the CA + AA genotypes showed higher TGF-β1 than those carrying the CC genotype (OR 1.35, 95% CI 1.001–1.054, p = 0.043). No association was observed between the genotypes and disability, disability progression and IL-10 levels.
These results suggest that the A allele of FOXP3 -3279 C > A variant may exert a role in the T regulatory cell function, which could be one of the factors involved in the susceptibility for MS in females.
KeywordsMultiple sclerosis Disability rs3761548 FOXP3 variant Transforming growth factor β1 T regulatory cell
Conception and research design: EMVR and ANCS; manuscript writing and discussion of results: EMVR, ANCS, and TF; data collection: DRK-M, WLCJP, TF, DFA, APK, and SRO, who contributed equally; laboratory analysis: TF, DFA, MABL, and KBO; statistical analysis: ANCS and DFA. All the authors have read and approved the final manuscript.
The study was supported by grants from Coordination for the Improvement of Higher Level of Education Personnel (CAPES) of Brazilian Ministry of Education; Institutional Program for Scientific Initiation Scholarship (PIBIC) of the National Council for Scientific and Technological Development (CNPq).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The protocol was approved by the Institutional Research Ethics Committees of University of Londrina, Paraná, Brazil (CAAE: 22290913.9.0000.5231) and all the individuals invited were informed in detail about the research and gave written Informed Consent.
- 21.Roxburgh RHSR, Seaman SR, Masterman T, et al. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology. 2005;64:1144–51. https://doi.org/10.1212/01.WNL.0000156155.19270.F8.CrossRefGoogle Scholar
- 23.Brazil. Brazilian Institute of Geography and Statistics (IBGE). Characteristics of the population and households: results of the universe. 2011; https://ww2.ibge.gov.br/english/estatistica/populacao/censo2010/caracteristicas_da_populacao/default_caracteristicas_da_populacao.shtm. Accessed 3 Jul 2018.
- 30.Hassanzadeh G, Hosseini Quchani S, Sahraian MA, et al. Leukocyte Gene expression and plasma concentration in multiple sclerosis: alteration of transforming growth factor-βs, claudin-11, and matrix metalloproteinase-2. Cell Mol Neurobiol. 2016;36:865–72. https://doi.org/10.1007/s10571-015-0270-y.CrossRefGoogle Scholar
- 32.Carrieri PB, Provitera V, De Rosa T, et al. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis. A correlation with clinical activity. Immunopharmacol Immunotoxicol. 1998;20:373–82. https://doi.org/10.3109/08923979809034820.CrossRefGoogle Scholar
- 33.Nicoletti F, Di Marco R, Patti F, et al. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b). Clin Exp Immunol. 1998;113:96–9.CrossRefGoogle Scholar
- 34.Mokhtarian F, Shi Y, Shirazian D, et al. Defective production of anti-inflammatory cytokine, TGF-beta by T cell lines of patients with active multiple sclerosis. J Immunol. 1994;52:6003–10.Google Scholar
- 35.Correale J, Gilmore W, McMillan M, et al. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol. 1995;154:2959–68.Google Scholar
- 49.Rich S, Seelig M, Lee HM, Lin J. Transforming growth factor beta 1 costimulated growth and regulatory function of staphylococcal enterotoxin B-responsive CD8+ T cells. J Immunol. 1995;155:609–18.Google Scholar